Patents Assigned to Larreacorp, Ltd.
  • Patent number: 6039955
    Abstract: A nontoxic, therapeutic agent having pharmacological activity comprising concentrated extract of Larrea tridentata plant material and ascorbic acid, an ascorbic acid ester, an ascorbic acid salt, butylated hydroxyanisole, butylated hydroxytoluene, hydrogen sulfide, hypophosphorous acid, monothioglycerol, potassium bisulfite, propyl gallate, sodium bisulfite, sodium hydrosulfite, sodium thiosulfate, sulfur dioxide, sulfurous acid, a tocopherol or vitamin E is made by a process in which the plant material is extracted using an organic solvent, preferably acetone, and is then saturated with one of the listed reducing agents acid to reduce the toxic NDGA quinone, which naturally occurs in the plant material, to NDGA itself.
    Type: Grant
    Filed: June 10, 1999
    Date of Patent: March 21, 2000
    Assignee: Larreacorp, Ltd.
    Inventors: Robert A. Sinnott, W. Dennis Clark, Kenneth Frank DeBoer
  • Patent number: 6004559
    Abstract: A nontoxic, therapeutic agent having pharmacological activity comprising concentrated extract of Larrea tridentata plant material and ascorbic acid, an ascorbic acid ester, an ascorbic acid salt, butylated hydroxyanisole, butylated hydroxytoluene, hydrogen sulfide, hypophosphorous acid, monothioglycerol, potassium bisulfite, propyl gallate, sodium bisulfite, sodium hydrosulfite, sodium thiosulfate, sulfur dioxide, sulfurous acid, a tocopherol, or vitamin E is made by a process in which the plant material is extracted using an organic solvent, preferably acetone, and is then saturated with one of the listed reducing agents acid to reduce the toxic NDGA quinone, which naturally occurs in the plant material, to NDGA itself.
    Type: Grant
    Filed: September 11, 1998
    Date of Patent: December 21, 1999
    Assignee: Larreacorp, Ltd.
    Inventors: Robert A. Sinnott, W. Dennis Clark, Kenneth Frank DeBoer
  • Patent number: 5945106
    Abstract: A nontoxic, therapeutic agent having pharmacological activity comprising concentrated extract of Larrea tridentate plant material and ascorbic acid is made by a process in which the plant material is extracted using an organic solvent, and is then saturated with ascorbic acid to reduce the toxic NDGA quinone, which naturally occurs in the plant material, to NDGA itself. Additional amounts of ascorbic acid are added to the extract to inhibit the natural oxidation of the NDGA into the toxic NDGA quinone in vivo, or during processing or storage. The resulting extract is useful in the treatment of viral diseases caused by viruses from the Herpesviridae family or viruses which require the Sp1 class of proteins to initiate viral replications. The resulting compound can also be used as an anti-inflammatory when the inflammatory diseases are mediated by the effects of leukotrienes. The listed reducing agents can also be used to stabilize NDGA as a therapeutic agent or a food additive.
    Type: Grant
    Filed: September 11, 1998
    Date of Patent: August 31, 1999
    Assignee: Larreacorp, Ltd.
    Inventor: Robert A. Sinnott
  • Patent number: 5837252
    Abstract: A nontoxic, therapeutic agent having pharmacological activity comprising concentrated extract of Larrea tridentata plant material and ascorbic acid, an ascorbic acid ester, an ascorbic acid salt, butylated hydroxyanisole, butylated hydroxytoluene, hydrogen sulfide, hypophosphorous acid, monothioglycerol, potassium bisulfite, propyl gallate, sodium bisulfite, sodium hydrosulfite, sodium thiosulfate, sulfur dioxide, sulfurous acid, a tocopherol, or vitamin E is made by a process in which the plant material is extracted using an organic solvent, preferably acetone, and is then saturated with one of the listed reducing agents acid to reduce the toxic NDGA quinone, which naturally occurs in the plant material, to NDGA itself.
    Type: Grant
    Filed: October 7, 1996
    Date of Patent: November 17, 1998
    Assignee: Larreacorp, Ltd.
    Inventors: Robert A. Sinnott, W. Dennis Clark, Kenneth Frank DeBoer